Matching articles for "teplizumab"
In Brief: An Expanded Indication for Teplizumab (Tzield)
The Medical Letter on Drugs and Therapeutics • June 22, 2026; (Issue 1757)
The CD3-directed monoclonal antibody teplizumab (Tzield –
Provention Bio), which was previously approved by the FDA to
delay the onset of stage 3 type 1 diabetes in patients ≥8 years
old with stage 2...
The CD3-directed monoclonal antibody teplizumab (Tzield –
Provention Bio), which was previously approved by the FDA to
delay the onset of stage 3 type 1 diabetes in patients ≥8 years
old with stage 2 type 1 diabetes, has now been approved for
such use in children 1-7 years old.
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • January 9, 2023; (Issue 1667)
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type...
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available in the
US that delays the onset of type 1 diabetes.